The Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science | 21 – 25 March 2025 | Adelaide Convention Centre

Sponsored Symposia

Please indicate your attendance at the Sponsored Symposia at the time of registration. If you are already registered for the ASM and wish to attend a sponsored symposia, or have any questions, contact us via email at tsanzsrs@theconferencecompany.com. 
If you have not yet registered for the ASM, you can register as part of the online registration form here.

Saturday, 22nd March 2025

Overview of the current and future treatments in Interstitial Lung Disease 

Time: 6pm - 7.30pm

Synopsis: Boehringer Ingelheim aims for this informative session to explore the evolving landscape of interstitial lung disease (ILD). The suggested topic and agenda on this symposium will focus on providing an update on the current treatment landscape in ILD, highlighting the unmet clinical needs and future ILD treatments that may address these gaps.

 

 

Sunday, 23rd March 2025

More than meets the eosinophil: the evolving science of interleukin-5 in airway type-2 inflammation 

Time: 7.15am -8.15am (breakfast served at 6.45am)

Speakers: Professor Gary Anderson, Professor Phil Bardin, Dr Angela Moran

Synopsis: Interleukin-5 (IL-5) is well known for its critical role in eosinophil generation, activation and survival, and therefore has been a therapeutic target in Type 2 inflammatory airways disease. This symposium aims to delve into the emerging evidence demonstrating multifaceted roles of IL-5 beyond its traditional understanding. 

Hear from internationally renowned experts on the evidence demonstrating the potential impact IL-5 has on epithelial barrier integrity, immune cell dysfunction and airway remodelling, presented in the context of clinical practice and anti-IL-5 intervention in airways disease.

Join us for this enlightening symposium to stay at the forefront of IL-5 research and its transformative potential in managing Type 2 inflammatory diseases.

 

 

Inhale, Exhale, Innovate: Breathing Sustainability into Inhaler Design 

Time: 7.15am -8.15am (breakfast served at 6.45am)

Chair: Professor Helen Reddel

Speakers: Professor John Blakey, Professor Christine Jenkins, Professor David Price 

Synopsis: Understanding the aspects of respiratory medicine that contribute to climate change is a critical first step in mitigating emissions. Some actions can be taken by individuals whilst others must be taken by the pharmaceutical industry who have an obligation to invest in technology to lower the global warming potential of the propellants in currently available pMDIs (considered F-gases).

This session presents technologies and strategies to reduce carbon emissions in respiratory medicine while maintaining patient care and patient choice.

Prof John Blakey will cover the development of carbon-minimal inhalers, outlining the pathway from preclinical research to commercialisation and provide a review of current programs.

Prof. Christine Jenkins will address the environmental impact of SABA overuse, a major source of emissions in asthma treatment, and discuss clinical strategies to manage overuse, improve asthma control, and reduce environmental harm.

Finally, new research on Maintenance and Reliever Therapy (MART) will be presented by Prof David Price highlighting the potential for MART to reduce greenhouse gas emissions while maintaining asthma control.

The session aims to equip healthcare professionals with the tools to transition to high value, low carbon healthcare.

 

 

Lung Cancer Screening Program

Time: 1.00pm -3.30pm 

 

 

Lung Cancer: Practical implications for Respiratory services/teams in 2025

Time: 6pm - 7.30pm

Co-chairs: Associate Professor Henry Marshall and Dr Tracy Leong

Speakers: Professor Kwun Fong, Professor Fraser Brims, Dr Vanessa Brunelli and Dr Gerry Olive

Synopsis: Respiratory physicians are pivotal in the diagnosis and early management of people with lung cancer. They are typically the first specialist that a patient is referred to and play a critical role in the lung cancer multi-disciplinary management team (MDT).

Changes to lung cancer classifications, the introduction of new guidelines for the management of incidental pulmonary nodules and the interface between primary care and specialist respiratory care can have sustainable impact and benefit in an evolving lung cancer environment, which includes the introduction of the National Lung Cancer Screening Program in July 2025. 

This symposium addresses a number of these considerations and will offer an update on what is new together with practical guidance on implementation to support respiratory physicians and colleagues in the diagnosis and management of lung cancer.

 

Monday, 24th March 2025

Severe Asthma: Beyond the Biomarkers

Time: 7.15am -8.15am (breakfast served at 6.45am)

Speakers: Associate Professor Marco Caminati, MD and Associate Professor John Blakey

Synopsis: We are pleased to invite you to the AstraZeneca Sponsored Breakfast Symposium, “Severe Asthma - Beyond theBiomarkers.” There have been significant advances in the understanding and management of severe asthma in recent times with the development of novel biologic therapies. Despite this, optimal selection and use of targeted therapies maybe complicated by disease heterogeneity, as severe asthma patients frequently present with a range of clinical features, phenotypes and comorbidities. This symposium will address a range of topical challenges in severe asthma management, including the role of biomarkers and patient phenotypes in therapy selection, consideration of upstream and downstream molecular targets, assessment and optimisation of patient response, and considerations for switching biologic agents. Expert speakers will discuss the evidence supporting current severe asthma management strategies, and how these can be practically integrated into clinical practice.

 

 

Dust and disease

Time: 7.15am -8.15am (breakfast served at 6.45am)

Speaker: Dr Ryan Hoy

 

 

What next for COPD?  Biomarkers, phenotypes, endotypes and targeted treatment

Time: 7.15am -8.15am (breakfast served at 6.45am)

Speakers: Professor Phil Bardin, Dr Sanjay Ramakrishnan and Assistant Professor Katrina Tonga

Synopsis: National thought leaders review and discuss the emerging understanding of Chronic Obstructive Pulmonary Disease (COPD) pathophysiology, recognise

diverse phenotypes and endotypes that drive disease progression and explore the evolving therapeutic landscape targeting drivers of COPD pathophysiology.